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Nuclear importgh risk human papillomavirus type 16 (HPV16) binds and inactivates the
retinoblastoma (RB) family of proteins. Our previous studies suggested that HPV16 E7 enters the nucleus via
a novel Ran-dependent pathway independent of the nuclear import receptors (Angeline, M., Merle, E., and
Moroianu, J. (2003). The E7 oncoprotein of high-risk human papillomavirus type 16 enters the nucleus via a
nonclassical Ran-dependent pathway. Virology 317(1), 13–23.). Here, analysis of the localization of speciﬁc E7
mutants revealed that the nuclear localization of E7 is independent of its interaction with pRB or of its
phosphorylation by CKII. Fluorescence microscopy analysis of enhanced green ﬂuorescent protein (EGFP) and
2xEGFP fusions with E7 and E7 domains in HeLa cells revealed that E7 contains a novel nuclear localization
signal (NLS) in the N-terminal domain (aa 1–37). Interestingly, treatment of transfected HeLa cells with two
speciﬁc nuclear export inhibitors, Leptomycin B and ratjadone, changed the localization of 2xEGFP-E738–98
from cytoplasmic to mostly nuclear. These data suggest the presence of a leucine-rich nuclear export signal
(NES) and a second NLS in the C-terminal domain of E7 (aa 38–98). Mutagenesis of critical amino acids in the
putative NES sequence (76IRTLEDLLM84) changed the localization of 2xEGFP-E738–98 from cytoplasmic to
mostly nuclear suggesting that this is a functional NES. The presence of both NLSs and an NES suggests that
HPV16 E7 shuttles between the cytoplasm and nucleus which is consistent with E7 having functions in both
of these cell compartments.
© 2008 Elsevier Inc. All rights reserved.IntroductionInfection caused by human papillomaviruses (HPVs) is associated
with more than 99% of cervical cancers. Over 200 HPV genotypes have
been identiﬁed, and 30 are known to infect anogenital mucosal
epithelial tissues. Mucosal HPVs have demonstrated different degrees
of oncogenic potential, with some classiﬁed as “high risk”, such as,
types 16, 18, 31 and 45, and others as “low risk”, such as, types 6 and
11. High risk HPVs are frequently detected in invasive cervical
carcinomas, whereas the low risk types are more often associated
with benign exophytic condylomas (zur Hausen, 2000).
Replication of HPVs is intimately connected to the differentiation
program of host epithelial cells. As HPVs depend on the host cell's
replication machinery for generation of viral progeny, they have
evolved the early proteins E6 and E7 that are able to induce the
differentiated cell to maintain active DNA replication machinery
which is necessary during viral replication (Jones and Munger, 1996;
Rapp and Chen, 1998). In HPV-positive genital cancers or carcinoma
cell lines, the integration of the viral genomes HPV16 or 18 into theclear localization signal; NES,
t protein; GST, glutathione-S-
l rights reserved.cellular genome results in the loss of expression of the viral E2 gene
and high levels of the E6 and E7 oncoproteins. High risk HPV E6 and E7
proteins can induce cellular immortalization and transformation
cooperatively, and are necessary for the induction and maintenance
of the transformed state (Rapp and Chen, 1998). Studies in transgenic
mice suggest that whereas E7 promotes the formation of benign
tumors, E6 acts primarily to accelerate progression of these benign
tumors to the malignant stage (Song et al., 2000). Genomic instability
is a hallmark of cervical carcinomas and high risk HPV E6 and E7 can
rapidly induce numerical and structural chromosome instability
(Duensing and Munger, 2004).
High risk HPV16 E7 oncoprotein is a phosphoprotein of 98 amino
acids and it is structurally and functionally related to Adenovirus E1A
protein. HPV16/18 E7 oncoproteins bind and inactivate several nuclear
proteins involved in the control of cell growth including retinoblas-
toma protein (pRB), and the RB-related pocket proteins, p107 and p130
(Dyson et al., 1992, 1989; Munger et al., 1989a). E7 oncoproteins also
interact with multiple components of the cell cycle machinery,
including E2F/cyclin A complex, cyclin E and the cyclin-dependent
kinase inhibitors p27 andp21 (Jones andMunger,1996; Zwerschke and
Jansen-Durr, 2000). HPV16 E7 also has target proteins localized in the
cytoplasm such as the microtubule-associated N-end rule ubiquitin
ligase p600 (Huh et al., 2005), suggesting that E7 has functions
mediated in the cytoplasm in addition to its nuclear functions.
Fig. 1. (A) EGFP-16E7 localizes mostly to the nucleus in HeLa cells in vivo. HeLa cells
were transfected with either EGFP-E7 (panels a and b), or EGFP (panels c and d)
plasmids and examined by ﬂuorescence microscopy at 24 h post transfection. Panels a
and c represent the ﬂuorescence of the EGFP and panels b and d the DAPI staining of the
nuclei. (B) The HPV16 E7ΔDLYC variant deﬁcient in binding pRB is mostly nuclear in
vivo. HeLa cells were transfected with EGFP-E7ΔDLYC plasmid and examined by
ﬂuorescencemicroscopy at 24 h post transfection. Panel a represents the ﬂuorescence of
the EGFP and panel b the DAPI staining of the nuclei.
Fig. 2. An HPV16 E7 variant deﬁcient in CKII phosphorylation is nuclear like the wild
type E7. HeLa cells were transfectedwith either EGFP-E7ΔEDE (panels A and B) or EGFP-
E7 (panels C and D) plasmids and examined by ﬂuorescence microscopy at 24 h post
transfection. Panels A and C represent the ﬂuorescence of the EGFP and panels B and D
the DAPI staining of the nuclei.
61A.A. Knapp et al. / Virology 383 (2009) 60–68HPV16 E7 consists of three domains: CR1 (aa 1–15), CR2 (aa 16–37)
and CR3 (aa 38–98), the C-terminal domain involved in binding Zn and
dimerization. The CR2 domain contains both the pRB binding site and
the CKII phosphorylation site (Munger et al., 2001). High risk HPV16
E7 is predominantly a nuclear protein in invasive cervical carcinoma
in situ, in the CaSki cervical carcinoma cell line and also when
expressed transiently in different cell lines like HaCaT, Vero, and U2OS
(Guccione et al., 2002; Fiedler et al., 2004; Cid-Arregui et al., 2003). In
cervical biopsies the high levels of nuclear HPV16 E7 correlate with
reduced pRB levels during progression to carcinomas, suggesting that
E7-dependent pRB degradation occurs in vivo (Fiedler et al., 2004). It
was suggested, using transfection assays, that a region of HPV16 E7 (aa
16–41) can localize a reporter protein into the nucleus (Fujikawa et al.,
1994). We have previously analyzed the nuclear import of HPV16 E7 in
import assays in digitonin-permeabilized cells and discovered that it
enters the nucleus via a novel Ran-dependent pathway that is
independent of karyopherin β import receptors (importins) (Angeline
et al., 2003). This is in agreement with HPV16 E7 not having a
canonical basic NLS or any other characterized NLS known to interact
with karyopherins/importins.
In order to map the NLS of HPV16 E7 and characterize the
requirements for nuclear localizationwe used transfection assays with
EGFP and 2xEGFP fusion plasmids containing E7 wild type, or E7
mutants or different E7 domains followed by ﬂuorescence microscopy
analysis of the intracellular localization. These in vivo experiments
were complemented by in vitro nuclear import assays with GST-fusion
proteins containing either wild type E7 or different E7 domains.Our data revealed that neither binding of pRB nor phosphoryla-
tion of E7 by CKII is required for nuclear localization of HPV16 E7.
Interestingly, we discovered that HPV16 E7 contains an nNLS in the
N-terminal domain (aa 1–37 containing both CR1 and CR2
domains) and both a second cNLS and a leucine-rich nuclear
export signal (NES) in the CR3 domain (aa 38–98). The presence of
both NLSs and an NES is not surprising as HPV16 E7 is known to
interact with proteins localized both in the nucleus and in the
cytoplasm.
Results
Binding of E7 to pRB is not required for nuclear localization of HPV16 E7
To analyze the intracellular localization of HPV16 E7, we used
transient transfection experiments in HeLa cells with enhanced green
ﬂuorescence protein (EGFP) fused to the wild type E7. We made an
EGFP-E7 plasmid with the EGFP fused at the N terminus of E7 and
upon transfection of HeLa cells the translated EGFP-E7 fusion protein
was well expressed and localized mostly in the nucleus (Fig. 1A, panel
a), in contrast with the EGFP itself which, as expected, was localized
throughout the cell (Fig. 1A, panel c).
We also made an E7-EGFP construct where the EGFP was placed
at the C terminus of E7. Upon transfection of HeLa cells with this
plasmid the resultant E7-EGFP fusion protein was localized in the
cytoplasm, suggesting that when the EGFP is located at the C
terminus of E7 it blocks the NLS and nuclear localization of E7 (data
not shown).
We have previously shown that the E7ΔDLYC variant defective in
binding pRB is imported into the nucleus in digitonin-permeabilized
cells as the wild type E7 (Angeline et al., 2003). Here, we investigated
the localization of the E7ΔDLYC variant in vivo and again found that it
has a similar nuclear localization much as the E7 wild type (Fig. 1B,
panel a) conﬁrming our previous in vitro data. These results suggest
that binding of HPV16 E7 to pRB is not required for the nuclear import
and localization of E7 oncoprotein.
Fig. 3. EGFP-E71–37 localizes mostly to the nucleus in transfected cells. HeLa cells were
transfected with either EGFP-E7 (panels A and B), or EGFP-E71–15 (panels C and D), or
EGFP-E71–37 (panels E and F), or EGPF (panels G and H) plasmids and examined by
ﬂuorescence microscopy at 24 h post transfection. Panels A, C, E and G represent the
DAPI staining of the nuclei and panels B, D, F and H the ﬂuorescence of the EGFP.
Fig. 4. EGFP-E738–98 is mostly cytoplasmic in transfected cells. HeLa cells were
transfected with either EGFP-E738–98 (panels A and B), or EGFP-E7 (panels C and D), and
examined by ﬂuorescence microscopy at 24 h post transfection. Panels A and C
represent the DAPI staining of the nuclei and panels B and D, the ﬂuorescence of the
EGFP.
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HPV16 E7
HPV16 E7 can be phosphorylated at two serines in positions 31/32
by casein kinase II (CKII) (Barbosa et al., 1990). The stretch of ﬁve acidic
residues on the carboxy-terminal side of the serine in HPV16 E7
(33EEEDE) is required for CKII recognition, and the mutant E7ΔEDE
cannot be phosphorylated by CKII (Munger et al., 1989b). We therefore
analyzed in vivo the localization of an EGFP-E7ΔEDE mutant in
comparison with EGFP-E7 to see if the E7 mutant that cannot be
phosphorylated has (or has not) a similar nuclear localization as the E7
wild type. Transient transfection experiments in HeLa cells revealed
that the EGFP-E7ΔEDE variant is mostly nuclear, similar to the E7 wild
type (Fig. 2, panels A and C), suggesting that CKII phosphorylation of
HPV16 E7 is not required for E7 nuclear import and localization in
vivo.
The N-terminal domain of HPV16 E7 contains a novel NLS
To map the NLS of HPV16 E7 we made EGFP fusion plasmids with
the domains of E7 and performed transient transfection assays in HeLa
cells. Fluorescence microscopy analysis revealed that the EGFP-E71–37
is localized mostly to the nucleus like the E7 wild type (Fig. 3, panels Band F), whereas the EGFP-E71–15 is throughout the cell like the EGFP
itself (Fig. 3, panels D and H). The EGFP-E738–98 is mostly cytoplasmic,
although there is also some nuclear localization (Fig. 4, panel B). These
data suggest that the N terminal domain (aa 1–37, containing both CR1
and CR2) of HPV16 E7 may contain an NLS. However, as the EGFP-E71–
37 is below the limit of passive diffusion through the nuclear pore
complex (around 40 kDa), its nuclear accumulation could be due
either to the presence of an NLS or to passive diffusion coupled with
nuclear retention.
Therefore to ﬁnely map the NLS of HPV16 E7 we generated a
plasmid containing a tandem copy of the EGFP fused to E7, because the
2xEGFP dimer is above the limit of passive diffusion through the
nuclear pore complex. After transfection of HeLa cells the 2xEGFP-E7
fusion protein was localized mostly into the nucleus in the majority of
transfected cells (Figs. 5A and B). We then made 2xEGFP fusions with
the domains of E7 and carried out transfection assayswith the 2xEGFP-
E7, 2xEGFP-E71–15, 2xEGFP-E71–37, 2xEGFP-E738–98, and 2xEGFP plas-
mids in HeLa cells. Analysis of the localization of the translated fusion
proteins showedmostly nuclear localization for the 2xEGFP-E7 and the
2xEGFP-E71–37 (Fig. 5A, panels a and e). This is similar with the nuclear
localization of the EGFP-E7 and EGFP-E71–37 (Fig. 3, panels B and F). In
contrast, both the 2xEGFP-E71–15 and 2xEGFP-E738–98 were cytoplas-
mic (Fig. 5A, panels c and g) as was the 2xEGFP itself (data not shown).
The difference in the localization between EGFP-E71–15 (throughout
the cell, Fig. 3, panel D) and 2xEGFP-E71–15 (cytoplasmic, Fig. 5A, panel
c) is due to the fact that the EGFP-E71–15 can enter the nucleus via
passive diffusion whereas the 2xEGFP-E71–15 cannot. Immunoblot
analysis with an anti-GFP antibody of the translated 2xEGFP-E7 fusion
proteins indicated that they were intact (data not shown), excluding
the possibility that the cytoplasmic localization of 2xEGFP-E71–15 and
2xEGFP-E738–98 is due toprotein degradation. Tomake sure thatwe are
not missing additional amino acids that may be part of the nNLS we
alsomade a 2xEGFP construct containing the E7 sequence aa 1–49.We
then transfected HeLa cells with either 2xEGFP-E7, or 2xEGFP-E71–37,
or 2xEGFP-E71–49 plasmids and analyzed the intracellular localization
via ﬂuorescence microscopy. Quantitation analysis of the number of
cells with either nuclear, cytoplasmic, or throughout the cell
ﬂuorescent staining in three experiments revealed that there is no
increase in the percent of cells with mostly nuclear ﬂuorescence
between 2xEGFP-E71–37 (70%) and 2xEGFP-E71–49 (46.67+/−1.9%)
(Fig. 5B); the decrease noticed for the nuclear localization of 2xEGFP-
E71–49 could be due to some potential folding problems of the E71–49
fragment. Overall these data indicate that the N-terminal domain of E7
(aa 1–37) contains anNLS (called nNLS)which canmediate the nuclear
localization of the EGFP and 2xEGFP reporter proteins in vivo.
Fig. 5. (A) Both the 2xEGFP-E7 and 2xEGFP-E71–37 are localized mostly in the nucleus in
vivo. HeLa cells were transfected with either 2xEGFP-E7 (panels a and b), or 2xEGFP-
E71–15 (panels c and d), or 2xEGFP-E71–37 (panels e and f), or 2xEGPF-E738–98 (panels g
and h) plasmids and examined by ﬂuorescence microscopy at 24 h post transfection.
Panels a, c, e and g represent the ﬂuorescence of the EGFP and panels b, d, f and h the
DAPI staining of the nuclei. (B) Quantitative analysis of the intracellular localization of
2xEGFP fusions with E7FL, E71–37, and E71–49. The data from three experiments have
been used for the graphic representation.White bars, mostly nuclear; black bars, mostly
cytoplasmic; gray bars, throughout the cell.
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and a second NLS
Cytoplasmic localization of a protein which has a size above the
limit of passive diffusion through the nuclear pore complex can be
the result of either the absence of an active NLS, or the presence of
both a leucine-rich NES and a weaker NLS. Leucine-rich NESs have
been identiﬁed in both cellular and viral proteins and they interact
with CRM1 nuclear export receptor. This nuclear export pathway
can be inhibited by two speciﬁc export inhibitors, Leptomycin B
(LMB) and ratjadone (RJA) which bind and inactivate CRM1 (Weis,
2003). We therefore examined the localization of the 2xEGFP-E738–
98 in the absence of any drug, or in the presence of either LMB or
RJA, as previously described (Strunze et al., 2005). Interestingly,
both LMB and RJA treatment consistently changed the localization
of the 2xEGFP-E738–98 protein from cytoplasmic to mostly nuclear
(Fig. 6, compare panels C and E with panel A). Quantitation analysis
of the percent of cells with nuclear versus cytoplasmic EGFP
ﬂuorescence showed a change from 84.1+/−4.8% cytoplasmic for
2xEGFP-E738–98 in the absence of a drug to 84.1+/−1.6% nuclear in
the presence of LMB and 81.8+/−6.4% nuclear in the presence of
RJA. Conversely, the LMB and RJA treatment had no signiﬁcant
effect on the localization of 2xEGFP-E71–15, 2xEGFP-E71–37, or
2xEGFP-E71–49 (data not shown). These data suggest the presence
of both a putative leucine-rich NES and a weaker NLS in the C
domain of E7 (aa 38–98). When the putative NES is inhibited by
either LMB or RJA treatment, the NLS in the C domain is able to
mediate the nuclear localization of the 2xEGFP-E738–98. As the
2xEGFP-E7 is localized mostly into the nucleus (Fig. 5, panel A) this
suggests that the nNLS and cNLS together override the putative
NES in the C domain in the context of the full length E7 protein in
HeLa cells. If a second NES is added to the C-terminus of EGFP-E7
(the strong NES of HIV Rev), the resultant EGFP-16E7-NESRev fusion
protein becomes cytoplasmic suggesting that the two NESs together
can overpower the two NLSs of E7 (data not shown). Moreover, in
the presence of the LMB inhibitor the EGFP-16E7-NESRev fusion
protein is re-localized mostly to the nucleus (data not shown)
suggesting that the cytoplasmic localization of EGFP-16E7-NESRev is
due to CRM1-mediated nuclear export and not because of
misfolding or masking the NLS of E7.
Examination of the E738–98 sequence shows the presence of two
overlapping putative NES sequences (76IRTLEDLLM84 and
79LEDLLMGTLGI89) that matched the consensus of an NES (L-X2–3-L-
X2–3-L-X-L; where L can be either L, I, V, F orM) (la Cour et al., 2004).
We introduced the following separate substitutions in the context of
2xEGFP-E738–98: I76 to A, L79 to A, 82LLM84 to AAA, or 87LGI89 to AAA.
After transient transfection in HeLa cells we analyzed the intracellular
localization of the resultant 2xEGFP-E738–98 NES mutants in compar-
isonwith the wild type. As shown in Fig. 7A the 2xEGFP-E738–98l/a and
2xEGFP-E738–98i/a mutants are mostly nuclear (panels c and e) in
contrast with the 2xEGFP-E738–98 wild type which is mostly
cytoplasmic (panel a). The 2xEGFP-E7llm/aaa is also mostly nuclear
(Fig. 7B, panel c) whereas for the 2xEGFP-E7lgi/aaa, the change in
localization was less dramatic (Fig. 7B, panel e). Quantitation analysis
of four experiments revealed that the most signiﬁcant changes in the
localization from cytoplasmic to nuclear are caused by the I76 to A, L79
to A, and 82LLM84 to AAA substitutions (Fig. 8). The 87LGI89 to AAA
substitution led to a less signiﬁcant change in localization (Fig. 8).
These data suggest that the sequence 76IRTLEDLLM84 is the main
functional NES for HPV16 E7 oncoprotein. However, the LGI amino
acids downstream from the NES allow for better nuclear export
mediated by this NES: when they are changed to alanines there is a
decrease in the percent of cells with mostly cytoplasmic localization
for 2xEGFP-E7lgi/aaa (Fig. 8).
The data from the LMB and RJA treatments or frommutagenesis of
critical amino acids in the NES suggest that there is also an NLS in the
Fig. 6. LMB and RJA, two inhibitors of leucine rich NES-mediated nuclear export, change the localization of the 2xEGFP-E738–98 protein from cytoplasmic to mostly nuclear. HeLa cells
were transfected with 2xEGPF-E738–98 plasmid in the absence of any drug (panels A and B), or in the presence of either LMB (panels C and D), or RJA (panels E and F) and examined by
ﬂuorescence microscopy at 24 h post transfection. Panels A, C and E represent the ﬂuorescence of the EGFP and panels B, D and F the DAPI staining of the nuclei.
64 A.A. Knapp et al. / Virology 383 (2009) 60–68C-terminal domain able to mediate nuclear import when the export is
blocked. To further analyze if the C domain of HPV16 E7 contains an
active NLS we tested a GST fusion protein with the C terminal domain
of HPV16 E7 in in vitro nuclear import assays. We used the GST-
16cE744–98 which contains the zinc ﬁnger domain for these experi-
ments. Digitonin-permeabilized HeLa cells were incubatedwith either
GST-E7, or GST-16cE744–98, or GST-NLS16L1 (as a positive control), or
GST (as a negative control) in the presence of HeLa cytosol. Both the
full length E7 and the cE744–98 were able to mediate the nuclear
import of the GST reporter, as was the positive control, the NLS16L1
(Fig. 9). The negative control, GST itself, remained out of the nucleus
(Fig. 9). These data indicate that the C terminal domain of E7 (aa 44–
98) contains an active NLS. Previously we have shown that GST-16E7
enters the nuclei of digitonin-permeabilized cells in the presence of
exogenous Ran and independent of karyopherins/importins (Angeline
et al., 2003). When we tested GST-16cE744–98 in import assays we
found that it can also enter the nuclei of digitonin-permeabilized cells
in the presence of only exogenous RanGDP (Fig. 10, panel B). As
expected the GST-M9 (M9 is the NLS of hnRNP A1 and interacts with
Kap β2 import receptor) entered the nuclei in the presence of RanGDP
plus Kap β2 import receptor (Fig. 10, panel E). The negative control
GST did not enter the nuclei in the presence of either RanGDP, or HeLa
cytosol (Fig. 10, panels H and I).
Discussion
In this study we investigated the requirements for the nuclear
localization of HPV16 E7 oncoprotein in vivo and identiﬁed its nuclear
transport signals. For this study we used EGFP and 2xEGFP fusions
with E7 wild type, E7 mutants or E7 domains in transfection assays in
HeLa cells and examined their intracellular localization.We used EGFPand 2xEGFP tags instead of a small tag like HA for two reasons: 1) to
increase the molecular weight of the fusion proteins (containing E7
fragments) so that we could distinguish between active nuclear
import or export mediated by an NLS or NES versus passive diffusion
coupled with nuclear or cytoplasmic retention, and 2) to avoid the
additional immunostaining step. Both the EGFP-E7 and 2xEGFP-E7
were mostly nuclear indicating that the EGFP tag at the N terminus of
E7 does not interfere with the nuclear localization of 16E7. This is in
agreement with previous reports showing that HA-E7 (the HA tag is at
the N terminus of E7) is predominantly nuclear when expressed in
both HaCaT and U2OS cells (Guccione et al., 2002). Interestingly, when
the EGFP tag was placed at the C terminus of E7, the resultant E7-EGFP
protein was mostly cytoplasmic, suggesting that it interferes with E7
nuclear localization (data not shown).
Analysis of the in vivo localization of HPV16 E7 deletion mutants
defective in either binding pRB or CKII phosphorylation revealed that
they are localized mostly to the nucleus as it is the case for the wild
type E7. These results indicate that neither binding of pRB nor CKII
phosphorylation of E7 is required for the nuclear import and
localization of HPV16 E7 oncoprotein.
Previously we discovered that HPV16 E7 oncoprotein enters the
nucleus via a novel Ran-dependent pathway which is independent of
the nuclear import receptors belonging to the karyopherin β/importin
β family (Angeline et al., 2003). This is in agreement with the fact
that HPV16 E7 has no classical basic NLS or other characterized type
of NLS motif known to interact with karyopherins/importins. To
identify the NLS(s) of E7 we performed in vivo localization expe-
riments of EGFP and 2xEGFP fusions with E7 domains. The results
suggest that HPV16 E7 oncoprotein contains two NLSs: one nNLS in
the N-terminal domain (aa 1–37, representing both CR1 and CR2
domains) and a second cNLS in the CR3 domain. Both NLSs were able
Fig. 7.Mutations of critical amino acids in a putative NES of E738–98 change its localization from cytoplasmic to mostly nuclear. (A) HeLa cells were transfected with either 2xEGPF-
E738–98wt (a and b), or 2xEGPF-E738–98l/a (c and d), or 2xEGFP-E738–98i/a (e and f) and examined by ﬂuorescence microscopy at 24 h post transfection. Panels a, c and e represent the
ﬂuorescence of the EGFP and panels b, d and f the DAPI staining of the nuclei. (B) HeLa cells were transfectedwith either 2xEGPF-E738–98wt (a and b), or 2xEGPF-E738–98llm/aaa (c and d),
or 2xEGFP-E738–98lgi/aaa (e and f) and examined by ﬂuorescence microscopy at 24 h post transfection. Panels a, c and e represent the ﬂuorescence of the EGFP and panels b, d and f the
DAPI staining of the nuclei.
65A.A. Knapp et al. / Virology 383 (2009) 60–68to mediate independently the nuclear localization of the 2xEGFP
reporter in HeLa cells. The cNLS also mediated the nuclear import of a
GST reporter in nuclear import assays in digitonin-permeabilized
cells in the presence of HeLa cytosol. The nuclear accumulation of
GST-cE744–98 in import assays (suggesting lack of nuclear export)
could be due to the depletion of CRM1 nuclear export receptor in the
digitonin-permeabilized cells. Importantly, the cNLS also mediatedFig. 8. Quantitative analysis of the intracellular localization of 2xEGFP-E738–98 and
corresponding NES mutants. The data from four experiments have been used for the
graphic representation. White bars, mostly nuclear; black bars, mostly cytoplasmic;
gray bars, throughout the cell.nuclear import in the digitonin-permeabilized cells in a Ran-
dependent manner and in the absence of Kap β import receptors as
previously shown for the full length 16E7 (Angeline et al., 2003).
Surprisingly, GST-E71–37 was not imported into the nucleus of
digitonin-permeabilized cells in the presence of either HeLa cytosol
or RanGDP (data not shown). This lack of nuclear import could be due
to either folding problems (causing aggregation) or masking the nNLSFig. 9. Nuclear import mediated by the 16E7 C-terminal domain. Digitonin-permeabi-
lized HeLa cells were incubated with either GST-E7 (panel A), GST-16cE744–98 (panel B),
GST-NLS16L1 (panel C), or GST (panel D) in the presence of HeLa cytosol and energy mix.
Note the nuclear import in panels A, B and C.
Fig. 10. Ran-mediated nuclear import of GST-16cE7. Digitonin-permeabilized HeLa cells were incubated with either GST-16cE744–98 (panels A to C), GST-M9 (panels D to F), or GST
(panels G to I) in the presence of transport buffer (panels A, D and G), RanGDP (panels B and H), RanGDP+Kap β2 (panel E), or HeLa cytosol (panels C, F and I). Note the nuclear import
in panels B, C, E and F.
66 A.A. Knapp et al. / Virology 383 (2009) 60–68by the GST reporter in this fusion protein, or requirement for an
exogenous factor/protein which has been depleted in the digitonin-
permeabilized cells.
Interestingly, our data with LMB and RJA nuclear export inhibitors
suggest that the CR3 domain of HPV16 E7 contains both a cNLS and a
leucine-rich NES. Examination of the CR3 domain sequence shows the
presence of two overlapping putative NES sequences (76IRTLEDLLM84
and 79LEDLLMGTLGI89) that matched the consensus of an NES
(LX2–3LX2–3LXL; L can be either L, I, V, F or M). Moreover, these
putativeNES sequences of E7 contain glutamate and aspartate residues
which have been shown to be prevalent in characterized NESs (la Cour
et al., 2004). In addition, the structure of the CR3 domain of E7 (Liu et
al., 2006) reveals that the N terminal part of these putative NESs is α-
helical which is also predominant for the characterized NESs based on
structural data available (la Cour et al., 2004).
Functional mutagenesis of critical amino acids in these putative
NESs revealed that it is the 76IRTLEDLLM84 sequence that is the main
functional NES involved in nuclear export of HPV16 E7. However, the
87LGI89 amino acids downstream the E7's NES allow for better nuclear
export activity of this NES. Previous reports indicated that the
16E7Δ79–83 deletion mutant was deﬁcient in inducing S phase in
differentiated keratinocytes (Helt et al., 2002), had reduced trans-
forming activity and no longer interacted with TATA box binding
protein (Massimi et al., 1997). The 79–83 deletion disrupts the
identiﬁed NES (76IRTLEDLLM84) and the resultant sequence now
becomes IRTMGTLGI which also matches the consensus of an NES
(LX2–3LX2–3LXL; L can be either L, I, V, F or M). If this putative NES
artiﬁcially created by deletion is not functional then the 16E7Δ79–83
mutant will be deﬁcient in nuclear export activity which may
contribute to its reduced activities.
Although HPV16 E7 contains only 98 amino acids and as a
monomer could enter and exit the nucleus via passive diffusion it has
been shown that E7 forms dimers (and perhaps oligomeric
complexes) in vivo and that the C terminal zinc binding domain is
critical for this dimerization activity (Clemens et al., 1995; Liu et al.,
2006). The presence of both NLSs and a leucine-rich NES in 16E7suggests that E7 actively shuttles between the nucleus and the
cytoplasm. This is not surprising as HPV16 E7 is known to interact
with both nuclear and cytoplasmic proteins and has been found to be
localized both in the nucleus and in the cytoplasm. The different
interactions of 16E7 with its nuclear and cytoplasmic targets could
regulate 16E7 nuclear import and export (via cytoplasmic or nuclear
retention) and consequently modulate the steady-state localization
of E7 in different cells and physiological conditions. The oligomer-
ization state of E7 could also inﬂuence the steady state localization of
E7. In this study in HeLa cells, although both the EGFP-E7 and
2xEGFP-E7 are mostly nuclear, there is also some cytoplasmic
localization (Figs. 1–3, 5A and B). Moreover, this cytoplasmic
localization of 2xEGFP-E7 remains even in the presence of LMB
and RJA export inhibitors, or NES mutations (data not shown),
suggesting that this small fraction of E7 is retained in the cytoplasm
via an interaction with a target protein(s). Interestingly, in invasive
cervical carcinoma in situ, 16E7 was also detected predominantly
into the nucleus of the tumor cells and to some extent in the cyto-
plasm (Fiedler et al., 2004) reﬂecting both nuclear and cytoplasmic
functions. Moreover, in transfected U-2OS cells when the protein
synthesis was blocked, some 10% of E7 remained cytoplasmic
suggesting that this fraction is retained in the cytoplasm via inter-
action with an E7 target protein (Fiedler et al., 2004). In our system
we did not notice differences in the intracellular localization of the
E7 proteins depending on their levels of expression. However, one
could speculate that because E7 is translated in the cytoplasm and
interacts with cytoplasmic proteins like p600 (Huh et al., 2005), at
low levels of E7 expression it is possible that the cytoplasmic
localization of E7 may be more predominant than nuclear localiza-
tion. The levels of CRM1 nuclear export receptor in different cells or
conditions may also inﬂuence the steady-state localization of 16E7
(and 16cE7) in those cells with high levels of CRM1 enhancing E7
nuclear export and cytoplasmic localization.
Recently, it has been shown that HPV16 E7 is able to change the
localization of steroid receptor coactivator 1 (SRC-1) from the nucleus
to the cytoplasm (Baldwin, et al., 2006). Future studies could explore if
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SRC1 from the nucleus to the cytoplasm.
Previous studies have identiﬁed and characterized the NLSs of
other HPV proteins. The L1 major and L2minor capsid proteins of both
high risk and low risk HPVs have classical basic monopartite and
bipartite NLSs (Bordeaux et al., 2006; Darshan et al., 2004; Merle et al.,
1999; Nelson et al., 2002; Sun et al., 1995). Low risk HPV11 E2 has a
classical monopartite NLS in the hinge region whereas high risk
HPV16 E2 has a novel alpha-helix NLS in the C domain (Klucevsek
et al., 2007; Zou et al., 2000). The HPV11 E1 DNA helicase has a
codominant bipartite NLS (Yu et al., 2007). In this study we discovered
that HPV16 E7 has two NLSs, one nNLS in the CR1 and CR2 domains
and a second cNLS in the CR3 domain. The cNLS mediates nuclear
import via a Ran-dependent pathwaywhich is independent of the Kap
β nuclear import receptors as we have previously shown for the full
length HPV16 E7 oncoprotein (Angeline et al., 2003). It remains to be
determined if the nNLS mediates nuclear localization in a similar
manner as the cNLS or differently. It will be interesting to determine
the critical amino acids in these two novel NLSs functioning in nuclear
import of HPV16 E7 and correlate the lack of nuclear import and
localization of E7 mutants with deﬁciencies in E7 functions. However,
it may be difﬁcult to ﬁnd speciﬁc E7 mutations deﬁcient in nuclear
import that do not interfere with one or more of the E7 interactions as
E7 has so many cellular targets. Moreover, as E7 has two NLSs, if one
NLS is impaired the other one can compensate for the nuclear
localization of E7.
One possible mechanism for E7 nuclear entry is via direct low
afﬁnity hydrophobic interactions between 16E7 and the FG (Phe-Gly)
repeats in nucleoporins, in a similar manner as the nuclear import
receptors (Weis, 2003). Preliminary experiments in support of this
model showed that HPV16 E7 can interact with a Phenyl-Sepharose
matrix (Knapp and Moroianu, observations unpublished) which
mimics the selectivity of the hydrophobic interactions of the FG
nucleoporins and binds all the nuclear import receptors (Ribbeck and
Gorlich, 2002).
The cNLS of HPV16 E7 is in the CR3 domain that contains the zinc-
ﬁnger domain (aa 58–94) consisting of two copies of a Cys-X-X-Cys
sequence motif separated by 29 amino acids. Interestingly, it has been
reported recently that the Tax protein of human T Lymphotropic Virus
Type 1 enters the nucleus via direct interactions with nucleoporins
containing phenylalanine-glycine (FG) repeats, and independent of
the nuclear import receptors. Functional studies revealed that the
zinc-ﬁnger domain of Tax functions as an NLS mediating the nuclear
import of Tax via direct interactions with FG nucleoporins (Tsuji et al.,
2007). In the future it will be interesting to analyze the interactions of
the cNLS of E7 with the FG-containing nucleoporins at the nuclear
pore complex.
Materials and methods
Generation of EGFP fusion plasmids with E7 wild type, E7 mutants and
different E7 domains
The enhanced green ﬂuorescent protein (EGFP) expression plasmid
pEGFP-C1 (Clontech, Inc.) was used to construct the EGFP fusion
protein expression plasmids (EGFP-E7, EGFP-E71–15, EGFP-E71–37,
EGFP-E738–98) as follows. The pEGFP-C1 plasmid was double digested
with EcoR1 and BamH1, run on a 0.7% agarose gel and the digested
vector was extracted using the protocol from the QIAquick Gel
Extraction Kit (Qiagen). DNA fragments spanning the full length
HPV16 E7 or the C domain (aa 38–98) were ampliﬁed using PCR
oligonucleotides that added EcoR1 and BamH1 restriction endonu-
clease sites and the PCR products were digested with EcoR1 and
BamH1 restriction enzymes and then ligated using T4 DNA ligase into
the EcoR1 and BamH1 cloning sites of pEGFP-C1. The resulting
plasmids were used to transform XL1-Blue cells and the puriﬁedplasmids were conﬁrmed by sequencing (MGH DNA Sequencing
Department). In all these EGFP fusion proteins the EGFP is at the N-
terminus of E7 or E7 fragments. It should be noted that we also made
an E7-EGFP construct where the EGFP was at the C terminus of E7.
The 2xEGFP-E7 and 2xEGFP-E738–98 were generated by ﬁrst using
PCR on the EGFP-E7 and EGFP-E738–98 with PCR oligonucleotides that
added SacII and XmaI restriction endonuclease sites, then digesting
the PCR products with SacII and XmaI restriction enzymes, and ﬁnally
ligating them into the SacII and XmaI cloning sites of pEGFP-C1 using
the T4 DNA ligase.
The EGFP-E71–15, EGFP-E71–37 and 2xEGFP-E71–15, 2xEGFP-E71–37
were generated using the QuikChange™ Site-Directed Mutagenesis
Kit from Stratagene with EGFP-E7 or 2xEGFP-E7 as a template
together with mutated primers containing a stop codon at aa 16 or
38. The EGFP-E7ΔDLYC and EGFP-ΔEDE were generated using the
QuikChange™ Site-Directed Mutagenesis Kit with EGFP-E7 as a
template together with mutated primers containing the correspond-
ing deletion. All the constructs were used to transform XL1 blue
bacteria and the puriﬁed plasmids were conﬁrmed by sequence
analysis (MGH DNA Sequencing Department).
Transient expressions and ﬂuorescence microscopy
HeLa cells (ATCC) were plated on 12 mm poly-L-lysine-coated glass
coverslips to 50–70% conﬂuency 24 h prior to transfection. Cells in
each well were transfected with the corresponding plasmid (as
indicated in Fig. legends) and FuGENE 6 reagent (Roche Applied
Science, IN) in 500 μl DMEM prepared following product protocol.
Media were changed to DMEM with 10% FBS and pen-strep after 5 h
and the cells were ﬁxed 24 h after the initial transfection with 10%
formaldehyde in PBS (10 min).
For the experiments with Leptomycin B (LMB), the LMB reagent
(Sigma) was added to the transfected cells at a ﬁnal concentration of
0.01 ng/ml in DMEM and incubated for 4 h before ﬁxation and
examination by ﬂuorescence microscopy. For the experiments with
Ratjadone A (RJA), the RJA reagent was added to the transfected
cells at a ﬁnal concentration of 10 ng/ml in DMEM and incubated for
4 h before ﬁxation and examination by ﬂuorescence microscopy.
Coverslips were mounted using Vectashield-Dapi mounting
medium (Vector Labs, CA) to identify the nuclei by DAPI staining
and examined by ﬂuorescence microscopy using a Nikon Eclipse TE
300 Microscope. The photos were taken at the same exposure time
with a Sony DKC-5000 camera or a SPOT RT3 camera equipped with
the Advanced SPOT computer software.
Preparation of GST fusion proteins with E7 wild type and E7 domains
The GST-16E7, GST-16E744–98 and GST-16E71–52 plasmids were
kindly provided by Dr. Karl Munger (Harvard Medical School, Boston)
and Dr. David Pim (ICGEB, Trieste, Italy). The GST-16E71–37 construct
was generated using the QuikChange™ Site-Directed Mutagenesis Kit
with the GST-E7 plasmid as a template together withmutated primers
containing a stop codon at aa 38. The GST-E71–37 plasmid was
transformed in XL1 blue bacteria and conﬁrmed by automated
sequence analysis (MGH DNA sequencing department). For protein
expression, the different GST-E7 plasmids were used to transform
E. coli BL21 CodonPlus. After induction of the bacteria with 1 mM
IPTG for 2 h at 30°, the GST-E7, GST-E71–37, and GST-E744–98 fusion
proteins were puriﬁed in their native state on glutathione-Sepharose
beads using a standard procedure. The GST-NLSHPV16L1 containing the
monopartite NLS (AKRKKRKL) of HPV16 L1 major capsid protein was
prepared as previously described (Nelson et al., 2002). The proteins
were checked for purity and lack of proteolytic degradation by SDS-
PAGE and Coomassie Blue staining. All the puriﬁed proteins were
dialyzed in transport buffer (20 mM HEPES-KOH, pH 7.3, 110 mM
potassium acetate, 2 mMmagnesium acetate, 1 mM EGTA, 2 mM DTT,
68 A.A. Knapp et al. / Virology 383 (2009) 60–68plus protease inhibitors (Moroianu et al, 1995), and stored in aliquots
at −80° C until use.
Nuclear import assays
The nuclear import assays were carried out as previously
described (Nelson et al., 2002). Brieﬂy, subconﬂuent HeLa cells,
grown on poly-L-lysine coated glass coverslips for 24 h, were
permeabilized with 70 μg/μl digitonin for 5 min on ice, and washed
with cold transport buffer. All import reactions contained an energy
regenerating system (1 mM GTP, 1 mM ATP, 5 mM phosphocrea-
tine, and 0.4 U creatine phosphokinase), HeLa cytosol (5 μl) and the
different GST-fusion proteins (as indicated in the Fig. legends). In
the experiments with recombinant transport factors, 2 μg RanGDP
and 1 μg Kap β2 were used per assay. The ﬁnal import reaction
volume was adjusted to 20 μl with transport buffer. For visualiza-
tion of nuclear import the GST fusion proteins were detected by
immunoﬂuorescence with an anti-GST antibody, as previously
described (Nelson et al., 2002). Coverslips were mounted using
Vectashield-DAPI mounting medium (Vector Labs, CA) to identify
the nuclei by DAPI staining. Nuclear import was analyzed with a
Nikon Eclipse TE 300 Microscope that has a ﬂuorescence attach-
ment and photos were taken with a Sony DKC-5000 camera or a
SPOT RT3 camera with the Advanced SPOT computer software.
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